{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T01:48:08Z","timestamp":1788486488603,"version":"build-2803163510"},"reference-count":78,"publisher":"American Society for Microbiology","issue":"6","license":[{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T00:00:00Z","timestamp":1780358400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Microbiol Spectr"],"published-print":{"date-parts":[[2026,6,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      Guideline-based combination therapy achieves sputum culture conversion rates in 23%\u201334% of patients with\n                      <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                      -complex lung disease. Thus, new therapies are needed. We performed a systematic review to validate and benchmark the hollow fiber system model of\n                      <jats:italic toggle=\"yes\">M. abscessus<\/jats:italic>\n                      lung disease for drug development. We performed a literature search to identify all published hollow fiber system pharmacokinetic-pharmacodynamic studies. Preferred Reporting Items for Systematic Reviews and Meta-Analyses was used for bias minimization. A total of 12 studies were identified. The average quality score was 13.7 out of 21. Eight were monotherapy (exposure-effect and dose-fractionation), one double \u03b2-lactam, and three guideline-based therapy studies. For omadacycline and imipenem, hollow fiber system data were accompanied by clinical real-world evidence confirmation. Microbial kill was always terminated by antimicrobial resistance. We used quantitative analyses to rank drugs\u2019 efficacy based on CFU\/mL kill below day 0 bacterial burden normalized to multi-drug guideline-based therapy kill. The highest-ranked drugs were sulbactam-durlobactam-ceftriaxone (177-fold), epetraborole (15-fold), and omadacycline (7-fold) better than guideline-based therapy. We used the target exposures identified in the systematic analysis in Monte Carlo experiments to identify optimal doses for inhaled formulations. The optimal inhalational dose of imipenem was 250 mg\/day, for tigecycline 4 mg\/day, for cefoxitin 50 mg\/day, and for amikacin liposome inhalation suspension 590 mg once weekly. The hollow fiber system model of\n                      <jats:italic toggle=\"yes\">M. abscessus<\/jats:italic>\n                      lung disease is tractable for exposure-effect, dose-fractionation, and factorial design combination studies. It could also be used to rank drugs and inform on which drugs to test in novel combinations.\n                    <\/jats:p>\n                    <jats:sec>\n                      <jats:title>IMPORTANCE<\/jats:title>\n                      <jats:p>\n                        Current treatments for\n                        <jats:italic toggle=\"yes\">Mycobacterium abscessus<\/jats:italic>\n                        lung disease fail in 70%\u201380% of patients and are toxic. The hollow fiber system has been used to study old and new potential treatments for this disease. We performed a systematic review of this methodology, for lessons learned. We found 12 studies, which were of adequate quality. Efficacy was always terminated by antimicrobial resistance. The top three drugs in terms of efficacy were sulbactam-durlobactam-ceftriaxone, epetraborole, and omadacycline, which were 7 to 177 times better than standard of care. These drugs could be combined into a new treatment regimen better than current treatments. We also calculated new doses for imipenem, tigecycline, cefoxitin, and amikacin when administered as inhalational therapy. The inhaled doses were multiple-fold lower than intravenous ones, which could be less toxic. The hollow fiber system model is an easily managed system from drug development and dose finding for\n                        <jats:italic toggle=\"yes\">M. abscessus<\/jats:italic>\n                        lung disease.\n                      <\/jats:p>\n                    <\/jats:sec>\n                  <\/jats:sec>","DOI":"10.1128\/spectrum.03296-25","type":"journal-article","created":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T13:20:49Z","timestamp":1776777649000},"update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":1,"title":["Systematic and quantitative analyses of hollow fiber model of\n                    <i>Mycobacterium abscessus<\/i>\n                    lung disease studies and new dosing recommendations"],"prefix":"10.1128","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8786-8851","authenticated-orcid":true,"given":"Shashikant","family":"Srivastava","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/01azfw069","id-type":"ROR","asserted-by":"publisher"}],"name":"Division of Infectious Diseases, Department of Medicine, The University of Texas at Tyler School of Medicine","place":["Tyler, USA"]},{"id":[{"id":"https:\/\/ror.org\/01sps7q28","id-type":"ROR","asserted-by":"publisher"}],"name":"Department of Cellular and Molecular Biology, University of Texas Health Science Center at Tyler, Center for Biomedical Research","place":["Tyler, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7592-8012","authenticated-orcid":true,"given":"Tawanda","family":"Gumbo","sequence":"additional","affiliation":[{"name":"NASOS Biotechnologies","place":["Dallas, USA"]},{"name":"IMPI Group of Companies","place":["Mt. Hampden, Zimbabwe"]},{"name":"Phase Advance","place":["Dallas, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201002-0310OC"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.congress-2015.pa2674"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.05041-22"},{"key":"e_1_3_4_5_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa241"},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01206-17"},{"key":"e_1_3_4_7_2","unstructured":"US Food and Drug Administration. 2025. FDA roadmap to reducing animal testing in preclinical safety studies. FDA U Bethesda Maryland. Available from: https:\/\/www.fda.gov\/files\/newsroom\/published\/roadmap_to_reducing_animal_testing_in_preclinical_safety_studies.pdf"},{"key":"e_1_3_4_8_2","unstructured":"European Medicines Agencies. 2025. Regulatory acceptance of new approach methodologies (NAMs) to reduce animal use testing. Available from: https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/research-development\/ethical-use-animals-medicine-testing\/regulatory-acceptance-new-approach-methodologies-nams-reduce-animal-use-testing"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02282-15"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2021.106549"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofab087"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.201711-2333OC"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-0770-2"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-020-60452-1"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.90.6.595"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.51353"},{"key":"e_1_3_4_17_2","doi-asserted-by":"publisher","DOI":"10.1038\/s42003-021-02184-0"},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200509-1531OC"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/167.6.1401"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/510079"},{"key":"e_1_3_4_21_2","volume-title":"Goodman & gilman\u2019s the pharmacological basis of therapeutics","author":"Gumbo T","year":"2018","unstructured":"Gumbo T. 2018. Chemotherapy of tuberculosis, Mycobacterium avium complex disease, and leprosy. In Brunton LL, Chabner B, Knollmann B (ed), Goodman & gilman\u2019s the pharmacological basis of therapeutics. McGraw Hill Medical, New York, NY."},{"key":"e_1_3_4_22_2","volume-title":"Goodman & gilman\u2019s the pharmacological basis of therapeutics","author":"Gumbo T","year":"2018","unstructured":"Gumbo T. 2018. General principles of chemotherapy of infectious diseases. In Brunton LL, Chabner B, Knollmann B (ed), Goodman & gilman\u2019s the pharmacological basis of therapeutics. McGraw Hill Medical, New York, NY."},{"key":"e_1_3_4_23_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ426"},{"key":"e_1_3_4_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ425"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ427"},{"key":"e_1_3_4_26_2","unstructured":"European Medicines Agencies. 2014. Dossier submitted for qualification opinion. hollow fiber system model of tuberculosis (HFS-TB) as an in vitro preclinical tool for optimization of dose selection and drug regimen in anti-TB drug development. Procedure number: EMEA\/H\/SAB\/049\/1\/QO\/2014\/SME. EMA London UK. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/other\/dossier-submitted-qualification-opinion-vitro-hollow-fibre-system-model-tuberculosis-hfs-tb_en.pdf"},{"key":"e_1_3_4_27_2","unstructured":"European Medicines Agencies. 2015. Qualification opinion on in-vitro hollow-fibre-system model of tuberculosis (HFS-TB). Available from: http:\/\/www.ema.europa.eu\/ema\/index.jsp?curl=pages\/includes\/document\/document_detail.jsp?webContentId=WC500181899&mid=WC0b01ac058009a3dc. Retrieved 31 Jan 2017."},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ484"},{"key":"e_1_3_4_29_2","first-page":"306","article-title":"The mathematical theory of communication. 1963","volume":"14","author":"Shannon CE","year":"1997","unstructured":"Shannon CE. 1997. The mathematical theory of communication. 1963. MD Comput 14:306\u2013317.","journal-title":"MD Comput"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.05546-11"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01681-08"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","unstructured":"Chapagain M Deshpande D Srivastava S Gumbo T. 2025. Systematic and quantitative analyses of pre-clinical Mycobacterium avium lung disease tools for drug development and transition from animal models to new approach methodologies. bioRxiv. doi:10.1101\/2025.07.10.664274:2025.07.10.664274","DOI":"10.1101\/2025.07.10.664274:2025.07.10.664274"},{"key":"e_1_3_4_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71"},{"key":"e_1_3_4_34_2","unstructured":"European Medicines Agencies. 2016. Guideline on the use of pharmacokinetics and pharmacodynamics in the development of antimicrobial medicinal products. EMA\/CHMP\/594085\/2015. Available from: https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-use-pharmacokinetics-pharmacodynamics-development-antimicrobial-medicinal-products_en.pdf"},{"key":"e_1_3_4_35_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.43.4.738"},{"key":"e_1_3_4_36_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaa110"},{"key":"e_1_3_4_37_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkac240"},{"key":"e_1_3_4_38_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.3c00395"},{"key":"e_1_3_4_39_2","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-020-00669-7"},{"key":"e_1_3_4_40_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/38.5.809"},{"key":"e_1_3_4_41_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkh326"},{"key":"e_1_3_4_42_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02651-18"},{"key":"e_1_3_4_43_2","doi-asserted-by":"publisher","DOI":"10.1096\/fasebj.11.11.9285481"},{"key":"e_1_3_4_44_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy608"},{"key":"e_1_3_4_45_2","volume-title":"Proceedings of the Physiological Society:Iv\u2013Vii","author":"Hill AV","year":"1910","unstructured":"Hill AV. 1910. The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves. Proceedings of the Physiological Society:Iv\u2013Vii."},{"key":"e_1_3_4_46_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.diagmicrobio.2024.116663"},{"key":"e_1_3_4_47_2","unstructured":"D\u2019Argenio DZ Schumitzky A Wang X. 2009. ADAPT 5 user\u2019s guide: pharmacokinetic\/pharmacodynamic systems analysis software biomedical simulations resource Los Angeles"},{"key":"e_1_3_4_48_2","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-022-01059-9"},{"key":"e_1_3_4_49_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.accpm.2024.101376"},{"key":"e_1_3_4_50_2","doi-asserted-by":"publisher","unstructured":"Deshpande D Srivastava S Gumbo T. 2025. Tigecycline pharmacodynamics in the hollow fiber system of Mycobacterium avium-complex lung disease and the utility of MICs and time-kill studies in drug development. Front Pharmacol. 2025:16:1682477.. doi:10.3389\/fphar.2025.1682477","DOI":"10.3389\/fphar.2025.1682477"},{"key":"e_1_3_4_51_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.276.5309.122"},{"key":"e_1_3_4_52_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.284.5420.1677"},{"key":"e_1_3_4_53_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.addr.2007.05.015"},{"key":"e_1_3_4_54_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.03112-15"},{"key":"e_1_3_4_55_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02821-15"},{"key":"e_1_3_4_56_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00990-16"},{"key":"e_1_3_4_57_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2023.106847:106847"},{"key":"e_1_3_4_58_2","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.03222-23"},{"key":"e_1_3_4_59_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiae601"},{"key":"e_1_3_4_60_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12941-025-00776-w"},{"key":"e_1_3_4_61_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf073"},{"key":"e_1_3_4_62_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkaf405"},{"key":"e_1_3_4_63_2","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01437-25"},{"key":"e_1_3_4_64_2","doi-asserted-by":"publisher","DOI":"10.5588\/ijtldopen.25.0173"},{"key":"e_1_3_4_65_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkz523"},{"key":"e_1_3_4_66_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2024.102519:102519"},{"key":"e_1_3_4_67_2","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofad423"},{"key":"e_1_3_4_68_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.idcr.2023.e01843"},{"key":"e_1_3_4_69_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.tube.2022.102269"},{"key":"e_1_3_4_70_2","doi-asserted-by":"publisher","DOI":"10.3389\/fpubh.2020.00190"},{"key":"e_1_3_4_71_2","volume-title":"Mefoxin\u00ae (Cefoxitin for injection)","author":"Merck & Co., Inc","year":"2006","unstructured":"Merck & Co., Inc. 2006. Mefoxin\u00ae (Cefoxitin for injection). MERCK & CO, INC., NJ, USA."},{"key":"e_1_3_4_72_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0140166"},{"key":"e_1_3_4_73_2","doi-asserted-by":"publisher","DOI":"10.3389\/fmicb.2018.02179"},{"key":"e_1_3_4_74_2","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciy623"},{"key":"e_1_3_4_75_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01553-20"},{"key":"e_1_3_4_76_2","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiad545"},{"key":"e_1_3_4_77_2","doi-asserted-by":"publisher","unstructured":"Gumbo T Chapagain M Magombedze G Srivastava S Deshpande D Pasipanodya JG Gumbo R Dheda K Diacon A Hermann D Hanna D. 2022. Novel tuberculosis combination regimens of two and three-months therapy duration. bioRxiv. doi:10.1101\/2022.03.13.484155:2022.03.13.484155","DOI":"10.1101\/2022.03.13.484155:2022.03.13.484155"},{"key":"e_1_3_4_78_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.45.1.13-22.2001"},{"key":"e_1_3_4_79_2","doi-asserted-by":"publisher","DOI":"10.1513\/AnnalsATS.202008-925OC"}],"container-title":["Microbiology Spectrum"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03296-25","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/spectrum.03296-25","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,17]],"date-time":"2026-06-17T13:09:38Z","timestamp":1781701778000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/spectrum.03296-25"}},"subtitle":[],"editor":[{"given":"Michael Gordon","family":"Whitfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,6,2]]},"references-count":78,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2026,6,2]]}},"alternative-id":["10.1128\/spectrum.03296-25"],"URL":"https:\/\/doi.org\/10.1128\/spectrum.03296-25","relation":{},"ISSN":["2165-0497"],"issn-type":[{"value":"2165-0497","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,2]]},"assertion":[{"value":"2025-10-16","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-12-18","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-04-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e03296-25"}}